Healthcare

Indians not 'guinea pigs', Covaxin's phase-3 trial not complete: Congress

Updated : January 13, 2021 05:06 PM IST

Bharat Biotech aims to dispatch around 55 lakh vaccines to 11 cities in the initial phase

As the government gears up for the Covid vaccination drive targeting healthcare and frontline workers, the Congress has cautioned the government that since the 'Covaxin' vaccine has not completed phase-3 trials, it should not be rolled out as Indians are not "guinea pigs".

Congress leader Manish Tewari said, "The government should not roll out vaccines till their efficacy is completely established and mandatory phase-3 trials are over, as Indians are not 'guinea pigs'."

His objections are over 'Covaxin' which has been approved for emergency use but has not completed phase-3 trials to prove its reliability. He said that the government is not giving a choice to the people. "Till yesterday NDA/BJP claimed Covaxin has been cleared for emergency use. Today by not allowing recipients to pick a vaccine of their choice is NDA/BJP making guinea pigs out of Indians. Is rollout the real phase-3 Trial of Covaxin?" he tweeted.

The first consignment of Bharat Biotech's Covaxin landed in Delhi from Hyderabad on Wednesday. Bharat Biotech aims to dispatch around 55 lakh vaccines to 11 cities in the initial phase, including Delhi, Bengaluru, Lucknow, Chennai, and Jaipur.

In Delhi, the Rajiv Gandhi Super Speciality Hospital (RGSSH) would receive 20,000 doses of Covaxin from a consignment that landed at the Indira Gandhi International Airport on Wednesday morning, officials said.

The RGSSH has already received 2.64 lakh doses of the 'Covishield' vaccine on Tuesday. The hospital has received 22 boxes consisting of 26,400 vials of 'Covishield', the Covid vaccine manufactured by the Serum Institute of India (SII).

Indians not 'guinea pigs', Covaxin's phase-3 trial not complete: Congress

You May Also Like

Bharat Biotech's Covaxin led to 'enhanced immune responses' in phase 1 trials, says Lancet

Phase 1 trial results show Covaxin has tolerable safety, enhanced immunity: Lancet study

Closing Bell: Sensex ends 746 points lower, Nifty down 1.5%; banking, metal sectors drag most

Trending on CNBC-TV18

recommended for you